VAERS Explorer
Back to explore

Report #2885552

Received Feb 14, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
PA
Recovered
Unknown
Vaccinated
Feb 3, 2026
Onset
Feb 3, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HIBVHIB (HIBERIX)GLAXOSMITHKLINE BIOLOGICALS37P7L9

Symptoms (1)

Product preparation issue

Symptom narrative

dose of Hiberix had accidentally been administered without proper reconstitution; dose of Hiberix had accidentally been administered without proper reconstitution; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 15-month-old male patient who received Hib (Hiberix) (batch number 7P7L9, expiry date 08-DEC-2026) for prophylaxis. On 03-FEB-2026, the patient received the 3rd dose of Hiberix. On 03-FEB-2026, an unknown time after receiving Hiberix, the patient experienced inappropriate preparation of medication (Verbatim: dose of Hiberix had accidentally been administered without proper reconstitution) and inappropriate dose of vaccine administered (Verbatim: dose of Hiberix had accidentally been administered without proper reconstitution). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date-11-FEB-2026 The reporter stated that, one dose of Hiberix had accidentally been administered without proper reconstitution, but they were unsure of which of the four patients that were involved received the improper dose. They were calling in to request information about any GlaxoSmithKline data concerning the administration of 3rd dose of Hiberix as they were unsure of which patient did not receive the correct dose and was planning on administering another to the patients involved. This was 1 of 4 linked cases, reported by same reporter for different patient.; Sender's Comments: US-GSK-US2026020496:SAME REPORTER US-GSK-US2026020497:SAME REPORTER US-GSK-US2026020508:SAME REPORTER US-GSK-US2026020508:Same reporter/Different patient